



*Am*

PTO/SB/21 (02-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|   |                        |                           |
|---|------------------------|---------------------------|
| <b>TRANSMITTAL FORM</b><br><br>(to be used for all correspondence after initial filing) | Application Number     | <b>10/529,090</b>         |
|   | Filing Date            | <b>September 30, 2005</b> |
|   | First Named Inventor   | <b>Kurt Lang et al.</b>   |
|   | Art Unit               | <b>1632</b>               |
|   | Examiner Name          |                           |
| Total Number of Pages in This Submission  | Attorney Docket Number | <b>20968</b>              |

| ENCLOSURES (Check all that apply)  |   |  |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form                                | <input type="checkbox"/> Drawing(s)                                       | <input type="checkbox"/> After Allowance communication to Group                            |
| <input type="checkbox"/> Fee Attached  | <input type="checkbox"/> Licensing-related Papers                         | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences        |
| <input type="checkbox"/> Amendment/Reply                                     | <input type="checkbox"/> Petition   | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final   | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information   |
| <input type="checkbox"/> Affidavits/declaration(s)                           | <input type="checkbox"/> Power of Attorney, Revocation                    | <input type="checkbox"/> Status Letter   |
| <input type="checkbox"/> Extension of Time Request                           | <input type="checkbox"/> Change of Correspondence Address                 | <input type="checkbox"/> Other Enclosure(s) (please identify below):                       |
| <input type="checkbox"/> Express Abandonment Request                         | <input type="checkbox"/> Terminal Disclaimer                              |  |
| <input checked="" type="checkbox"/> Information Disclosure Statement         | <input type="checkbox"/> Request for Refund                               |  |
| <input type="checkbox"/> Certified Copy of Priority Document(s)              | <input type="checkbox"/> CD, Number of CD(s) _____                        |  |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application    | Remarks   |  |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 |   |  |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT |                         |
|--|-------------------------|
| Firm or Individual name                    | <b>Brian C. Remy</b>    |
| Signature                                  |                         |
| Date                                       | <b>January 30, 2006</b> |

| CERTIFICATE OF TRANSMISSION/MAILING   |                      |                              |
|---|----------------------|------------------------------|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. |                      |                              |
| Typed or printed name   | <b>Brian C. Remy</b> |                              |
| Signature   |                      | Date <b>January 30, 2006</b> |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Group: 1632

Kurt Lang, Andreas Schaubmar, Ralf Schumacher

Examiner:

Application No. 10,529,090, filed September 30, 2005  
(Case Docket No. 20968)

For: **CONJUGATES OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4  
AND POLY(ETHYLENE GLYCOL)**

**INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110  
January 30, 2006

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1-A3, B1-B4 and C1-C35 are listed on Form PTO-1449. Documents B1-B4 and C1-C35 are enclosed. Documents A1-A3 are not enclosed as they are U.S. Patents.

Also enclosed is a Search Report, dated September 25, 2003, which was issued by the International Searching Authority in the corresponding PCT application. The Search Report lists Document C21, C22 and C30.

Application No. 10/529,090  
Filed: September 30, 2005

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application and/or because each item of information contained in the Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, no fee is due.

Respectfully submitted,



Attorney for Applicant(s)  
Brian C. Remy  
(Reg. No. 48176)  
340 Kingsland Street  
Nutley, New Jersey 07110  
Telephone: (973) 235-6516  
Telefax: (973) 235-2363

154677

[illegible]

|  |   |    |   |                          |                    |
|--|---|----|---|--------------------------|--------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use several sheets if necessary) |   |    |   | <b>Complete if Known</b> |                    |
|  |   |    |   | Application Number       | 10/529,090         |
|  |   |    |   | Filing Date              | September 30, 2005 |
|  |   |    |   | First Name Inventor      | Kurt Lang et al.   |
|  |   |    |   | Group Art Unit           | 1632               |
|  |   |    |   | Examiner Name            |                    |
| Sheet  | 2 | Of | 3 | Attorney Docket Number   | 20968              |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner<br>Initials <sup>7</sup> | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T <sup>2</sup>     |
|-----------------------------------|--------------------------|---|--------------------|
|                                   | C1                       | Yu et al., J. Natl. Cancer Inst., 92, pp. 1472-1489 (2000)  |                    |
|                                   | C2                       | Conover et al., J. Biol. Chem., 270, pp. 4395-4400 (1995)   |                    |
|                                   | C3                       | Miyakoshi et al., Endocrinology, 142, pp. 2641-2648 (2001)  |                    |
|                                   | C4                       | Byun et al., J. Endocrinology, 169, pp. 135-143 (2001)  |                    |
|                                   | C5                       | Mohan et al., Proc. Natl. Acad. Sci. USA, 86, pp. 8338-8342 (1989)  |                    |
|                                   | C6                       | Honda et al., J. Clin. Endocrinol. Metab., 81, pp. 1389-1396 (1996)   |                    |
|                                   | C7                       | Qin et al., J. Biol. Chem. 273, pp. 23509-23516 (1998)  |                    |
|                                   | C8                       | Kiefer et al., J. Biol. Chem., 267, pp. 12692-12699 (1992)  |                    |
|                                   | C9                       | Schiltz et al., J. Bone Mineral Res., 8, pp. 391-396 (1993)   |                    |
|                                   | C10                      | Culouscou et al., Cancer Res., 51, pp. 2813-2819 (1991)   |                    |
|                                   | C11                      | Damon et al., Endocrinology, 139, pp. 3456-3464 (1998)  |                    |
|                                   | C12                      | Diehl et al., J. Cancer Res. Clinical Oncol., 127, Suppl. 1, pp. S54 (2001)   |                    |
|                                   | C13                      | Hershfield et al, New England Journal of Medicine, 316, pp. 589-596 (1987)  |                    |
|                                   | C14                      | Myers et al., Clin. Pharmacol. Ther., 49, pp. 307-313 (1991)  |                    |
|                                   | C15                      | Katre, N.V., J. Immunol., 144, pp. 209-213 (1990)   |                    |
|                                   | C16                      | Clark et al., J. Biol. Chem., 271, pp. 21969-21977 (1996)   |                    |
|                                   | C17                      | Cunningham et al., Science, 254, pp. 821-825 (1991)   |                    |
|                                   | C18                      | Wojchowski et al., Biochem. Biophys. Acta, 910, pp. 224-232 (1987)  |                    |
|                                   | C19                      | Tanaka et al., Cancer Res., 51, pp. 3710-3714 (1991)  |                    |
|                                   | C20                      | Goodson et al., BioTechnology, 8, pp. 3433-346 (1990)   |                    |
|                                   | C21                      | Van Den Berg et al., Europ. J. Cancer, 33, pp. 1108-1113 (1997)   |                    |
|                                   | C22                      | Veronese, F.M., Biomaterials, 22, pp. 405-417 (2001)  |                    |
|                                   | C23                      | Kinstler et al., Adv. Drug Deliv. Rev., 54, pp. 477-485 (2002)  |                    |
|                                   | C24                      | Monfardini et al., Bioconjug. Chem., 6, pp. 62-69 (1995)  |                    |
|                                   | C25                      | March, J., Advanced Organic Chemistry, pp. 375-376 (1977)   |                    |
|                                   | C26                      | Duncan, R.J., Anal. Biochem., 132, pp. 68-73 (1983)   |                    |
|                                   |                          |   |                    |
| Examiner<br>Signature             |                          |   | DATE<br>CONSIDERED |

<sup>7</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation or abstract is attached.

